Evaluation of the Association Between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors Abstract #256

Introduction: Bone mineral density (BMD) and fractures are influenced by diet, activity, drugs and hormones. Recent studies highlight an inverse relationship between serotonin and BMD.
Aim(s): Two-centre investigation of the relationship between serotonin metabolites and BMD in patients with sporadic NETs with and without carcinoid syndrome.
Materials and methods: One-year prospective audit, patients undergoing DXA-scans as standard care for chronic malignancy. Following exclusions for confounders, there were 47 subjects (24 females, 59.1±16.0yrs, BMI 26.8±4.9, 23 males, 66.6±9.2yrs BMI 27.3±4.3): 32 gastrointestinal, 10 pancreatic, three pulmonary, and two other NETs. Forty (85.1%) had carcinoid syndrome.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Maralyn R Druce

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1935 Prevalence of Pancreatic Neuroendocrine Neoplasms with Serotonin Secretion
Introduction: Pancreatic neuroendocrine neoplasms (pNENs) are rare neoplasms and represent 1-2% of all pancreatic neoplasms. These tumors can secrete a variety of hormonally active substances producing distinct clinical symptoms, or can be clinically non-functioning. Pancreatic NENs that secrete serotonin are extremely rare, but their prevalence has not been explored adequately.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD, MSc, PhD Nikolaos Tsoukalas
#1812 Correlation of Plasma (p) and Urine (u) 5-HIAA Levels in Patients (pts) with Carcinoid Syndrome (CS) – Post-Hoc Analyses from the TELESTAR Study
Introduction: Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor in development for treating CS symptoms. During the double-blind treatment [DBT] period of the phase 3, 12-week, placebo-controlled TELESTAR study, TE was well tolerated and significantly reduced bowel-movement frequency and u5-HIAA levels compared with placebo (PBO) in NET patients with CS treated with a SSA.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: Marianne Pavel
#559 The Bone Scintigram in Patients with Neuroendocrine Tumors - A Series of 12 Cases
Introduction: The bone metastasis finding is based on imaging or aggressive features as high Ki-67 or rapidly progressive disease.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Mara Carsote
Keywords: neuroendocrine, bone
#595 A Single Fasting Plasma 5-HIAA Value Correlates with 24-Hour Urinary 5-HIAA Values and Other Biomarkers in Midgut Neuroendocrine Tumors (NETs)
Introduction: 5-hydoxyindoleacetic acid (5-HIAA) is used for the evaluation of neuroendocrine tumors (NETs), however, the current 5-HIAA assay requires a 24-hour urine collection which is inconvenient.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Eugene Woltering
#121 Serotonin synthesis inhibitors: a novel approach for managing gastrointestinal symptoms in carcinoid syndrome
Introduction: Carcinoid syndrome (CS) occurs when metastatic carcinoid tumors secrete large amounts of serotonin (5-HT) and other bioactive substances into systemic circulation, causing a variety of symptoms, including GI symptoms such as profound diarrhea. Reduction in 5-HT production by the tumor would be expected to improve symptoms in patients with CS.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jay L Mitchell